secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125385
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Q3 2024 net loss $7.7M; ODYSSEY Phase 2b wet AMD trial hits all endpoints
--------------------------------------------------------------------------------

- Net loss of $7.7M ($0.10 per share) vs. $9.3M ($0.15) in Q3 2023; revenue $1.0M, up from $0.9M.
- ODYSSEY Phase 2b of suprachoroidal CLS-AX in wet AMD met all primary and secondary outcomes with extended duration.
- Cash, equivalents and short-term investments $23.6M as of Sep 30, 2024; runway into Q3 2025.
- Asia-Pacific partner Arctic Vision licensed ARVN001 to Santen for China; Phase 3 UME data positive.
- Tony Gibney appointed Chair of Board; REGENXBIO advances ABBV-RGX-314 via SCS Microinjector toward pivotal trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017024125385/0000950170-24-125385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017024125385/clsd-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer